Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Bladder Cancer

Expert Opinion / Cases · May 07, 2021

Metastatic BC

Shafi Alam


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Guru Sonpavde

    May 15, 2021

    I would recommend avelumab switch-maintenance therapy now (within 4-10 weeks of last chemotherapy). Avelumab demonstrated improved overall survival (OS) as switch maintenance therapy in the JAVELIN-Bladder-100 phase III trial regardless of tumor PD-L1 expression in patients with metastatic urothelial carcinoma (mUC) who had stable or responding disease after 4-6 cycles of platinum-based first line chemotherapy (median OS 21.4 vs 14.3 months; HR, 0.69; 1-sided P = .0005). Switch maintenance avelumab also ensures early delivery of avelumab to a large fraction of patients when compared with the paradigm of administering a PD1/L1 inhibitor to those with progressive disease following a break from systemic therapy. The switch maintenance paradigm appeared to benefit patients regardless of tumor PD-L1 status, prior cisplatin vs carboplatin, quality of response (CR, PR, SD) and sites of metastasis (despite some trends, none of the sub-analyses were powered for definitive results). It is unclear if avelumab can be safely discontinued without compromising outcomes after a specific duration (especially in those with CR/PR) and a randomized ALLIANCE led study is evaluating this issue (NCT04637594) and should be supported.

  • Apr 19, 2024

    Pending Moderator approval.

Further Reading